Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective-Reference-Cited by-同舟云学术

Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective

Published:2019-04 Issue:10 Volume:15 Page:1067-1084
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Aapro Matti¹,Zhang Li²,Yennu Sriram³,LeBlanc Thomas W⁴,Schwartzberg Lee⁵

Affiliation:

1. Genolier Cancer Centre, Clinique de Genolier, Genolier, Switzerland

2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Medical Oncology Sun Yat-sen University Cancer Center, Guangzhou, PR China

3. Department of Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

4. Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC 27705, USA

5. Department of Hematology and Oncology, The West Clinic, Germantown, TN 38138, USA

Abstract

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0872

Reference104 articles.

1. Preference weights for chemotherapy side effects from the perspective of women with breast cancer

2. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer

3. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life

4. Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment

5. Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy;Tumors of female reproductive system;2023-10-27

2. [Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?;Farmacia Hospitalaria;2023-09

3. Guías antieméticas: ¿hemos incorporado los cambios referentes a carboplatino y antraciclinas?;Farmacia Hospitalaria;2023-09

4. Symptoms in Advanced Hematologic Malignancies and Other Serious Hematologic Conditions;Palliative Care in Hematologic Malignancies and Serious Blood Disorders;2023

5. Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy;Breast Care;2021-05-25